Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 study Kasper, S., Haddad, R., Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Monga, M., Lynch, M., Zhu, J., Shaw, J. W., Gillison, M. L., Harrington, K. J. KARGER. 2017: 250-+
View details for Web of Science ID 000411428400606